IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 2, 2010, Pages 872-877

  Kis, Loránd L ^a   Salamon, Daniel ^a   Persson, Emma K ^a,c   Nagy, Noémi ^a   Scheeren, Ferenc A ^b,d   Spits, Hergen ^b   Klein, George ^a   Klein, Eva ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c LUND UNIVERSITY   (Sweden)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epstein Barr virus; IL 21; Lymphoma; STAT3

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; EPSTEIN BARR VIRUS ANTIGEN 2; IMMUNOGLOBULIN; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 21; OCTAMER TRANSCRIPTION FACTOR 2; PROTEIN; PROTEIN BCL 6; PROTEIN LMP 1; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER CELL CULTURE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; LYMPHOCYTE PROLIFERATION; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION;

B-LYMPHOCYTES; CELL DIVISION; CELL LINE, TUMOR; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE EXPRESSION REGULATION, VIRAL; GENOME, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN J RECOMBINATION SIGNAL SEQUENCE-BINDING PROTEIN; INTERLEUKINS; LYMPHOMA, B-CELL; NEOPLASMS; PROMOTER REGIONS, GENETIC; VIRAL MATRIX PROTEINS; VIRAL PROTEINS; VIRUS LATENCY;

HUMAN HERPESVIRUS 4;

EID: 76249098582     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0912920107     Document Type: Article

References (51)

1. Young LS, Rickinson AB (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757-768.
2. Thorley-Lawson DA (2001) Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 1:75-82.
3. Klein E, Kis LL, Klein G (2007) Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene 26:1297-1305.
4. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS (1991) Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 337:320-322.
5. Fåhraeus R, et al. (1988) Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 42:329-338.
6. Chiang AK, Tao Q, Srivastava G, Ho FC (1996) Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer 68:285-290.
7. Chen CL, et al. (1993) Epstein-Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas. J Virol 67:6303-6308.
8. Gloghini A, et al. (2002) Expression of cyclin-dependent kinase inhibitor p27(Kip1) in AIDS-related diffuse large-cell lymphomas is associated with Epstein-Barr virus-encoded latent membrane protein 1. Am J Pathol 161:163-171.
9. Oudejans JJ, et al. (1995) Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders. Am J Pathol 147:923-933.
10. Capello D, et al. (2003)Molecular histogenesis of posttransplantation lymphoproliferative disorders. Blood 102:3775-3785.
11. Zettl A, et al. (2002) Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol 117:368-379.
12. Wang F, Tsang SF, Kurilla MG, Cohen JI, Kieff E (1990) Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol 64:3407-3416.
13. Zimber-Strobl U, et al. (1993) The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis-element of the terminal protein 1 gene promoter. EMBO J 12:167-175.
14. Sadler RH, Raab-Traub N (1995) The Epstein-Barr virus 3.5-kilobase latent membrane protein 1 mRNA initiates from a TATA-Less promoter within the first terminal repeat. J Virol 69:4577-4581.
15. Chen H, et al. (2001) Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors. J Virol 75:2929-2937.
16. Chen H, Hutt-Fletcher L, Cao L, Hayward SD (2003) A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus. J Virol 77:4139-4148.
17. Stewart S, et al. (2004) Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-kappaB transcription factor pathway. Proc Natl Acad Sci USA 101:15730-15735.
18. Spolski R, Leonard WJ (2008) Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 26:57-79.
19. King C, Tangye SG, Mackay CR (2008) T follicular helper (TFH) cells in normal and dysregulated immune responses. Annu Rev Immunol 26:741-766.
20. Ettinger R, Kuchen S, Lipsky PE (2008) The role of IL-21 in regulating B-cell function in health and disease. Immunol Rev 223:60-86.
21. Ettinger R, et al. (2005) IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol 175:7867-7879.
22. Konforte D, Paige CJ (2006) Identification of cellular intermediates and molecular pathways induced by IL-21 in human B cells. J Immunol 177:8381-8392.
23. Kis LL, Takahara M, Nagy N, Klein G, Klein E (2006) IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma- and NK lymphoma-derived cell lines. Blood 107:2928-2935.
24. Adler B, et al. (2002) Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1. Proc Natl Acad Sci USA 99:437-442.
25. Prince S, et al. (2003) Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. J Virol 77:5000-5007.
26. Kelly GL, et al. (2005) Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis. J Virol 79:10709-10717.
27. Floettmann JE, Ward K, Rickinson AB, Rowe M (1996) Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline- regulated expression in B cell lines. Virology 223:29-40.
28. Cuomo L, et al. (1992) Expression of the Epstein-Barr virus (EBV)-encoded membrane protein LMP1 impairs the in vitro growth, clonability and tumorigenicity of an EBV-negative Burkitt lymphoma line. Int J Cancer 51:949-955.
29. Diehl SA, et al. (2008) STAT3-mediated up-regulation of BLIMP1 Is coordinated with BCL6 down-regulation to control human plasma cell differentiation. J Immunol 180: 4805-4815.
30. Kempkes B, et al. (1995) B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J 14:88-96.
31. Rowe M, et al. (1987) Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 6: 2743-2751.
32. Kis LL, Takahara M, Nagy N, Klein G, Klein E (2006) Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1. Immunol Lett 104:83-88.
33. Bhende PM, Dickerson SJ, Sun X, Feng WH, Kenney SC (2007) X-box-binding protein 1 activates lytic Epstein-Barr virus gene expression in combination with protein kinase D. J Virol 81:7363-7370.
34. Sun CC, Thorley-Lawson DA (2007) Plasma cell-specific transcription factor XBP-1s binds to and transactivates the Epstein-Barr virus BZLF1 promoter. J Virol 81: 13566-13577.
35. Scheeren FA, et al. (2008) IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis. Blood 111:4706-4715.
36. Lamprecht B, et al. (2008) Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood 112:3339-3347.
37. de Leval L, et al. (2007) The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109:4952-4963.
38. Piccaluga PP, et al. (2007) Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res 67:10703-10710.
39. Dudziak D, et al. (2003) Latent membrane protein 1 of Epstein-Barr virus induces CD83 by the NF-kappaB signaling pathway. J Virol 77:8290-8298.
40. Saito M, et al. (2007) A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 12:280-292.
41. Teng Y, et al. (2007) IRF4 negatively regulates proliferation of germinal center B cell-derived Burkitt's lymphoma cell lines and induces differentiation toward plasma cells. Eur J Cell Biol 86:581-589.
42. Martins G, Calame K (2008) Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol 26:133-169.
43. Rochford R, Hobbs MV, Garnier JL, Cooper NR, Cannon MJ (1993) Plasmacytoid differentiation of Epstein-Barr virus-transformed B cells in vivo is associated with reduced expression of viral latent genes. Proc Natl Acad Sci USA 90:352-356.
44. Wendel-Hansen V, Rosén A, Klein G (1987) EBV-transformed lymphoblastoid cell lines down-regulate EBNA in parallel with secretory differentiation. Int J Cancer 39:404-408.
45. Altmeyer A, et al. (1997) Reversal of EBV immortalization precedes apoptosis in IL-6-induced human B cell terminal differentiation. Immunity 7:667-677.
46. Konforte D, Simard N, Paige CJ (2008) Interleukin-21 regulates expression of key Epstein-Barr virus oncoproteins, EBNA2 and LMP1, in infected human B cells. Virology 374:100-113.
47. Babcock GJ, Hochberg D, Thorley-Lawson AD (2000) The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13:497-506.
48. Kurth J, et al. (2000) EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity 13: 485-495.
49. Skak K, Kragh M, Hausman D, Smyth MJ, Sivakumar PV (2008) Interleukin 21: combination strategies for cancer therapy. Nat Rev Drug Discov 7:231-240.
50. Cuomo L, et al. (1990) Expression of the Epstein-Barr virus (EBV)-encoded membrane antigen (LMP) increases the stimulatory capacity of EBV-negative B lymphoma lines in allogeneic mixed lymphocyte cultures. Eur J Immunol 20:2293-2299.
51. Rowe M, et al. (1995) Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate upregulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol 25:1374-1384.